Vanda Pharmaceuticals Inc. (Vanda) today announced that the U.S. Food and Drug Administration (FDA) informed Vanda that the New Drug Application (NDA) for Bysantitm (milsaperidone) has been filed, and ...

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) informed ...

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) informed ...

Vanda Pharmaceuticals challenges the FDA over delays in addressing its hearing request for tradipitant, citing agency layoffs ...

Vanda Pharmaceuticals (VNDA) stated that “FDA bureaucrats have committed to delay Vanda’s request for a hearing on the approvability of ...

Vanda Pharmaceuticals Inc. ("Vanda") (Nasdaq: VNDA) today announced that FDA bureaucrats have committed to delay Vanda's ...

The Washington Capitals announced today ALL CAPS 2025 Playoffs initiatives presented by Vanda Pharmaceuticals Inc.

Value is just one of the five Stock Grades included in our A+ Investor service. AAII members can see the top-graded stocks—those with grades of A or B for value, growth, momentum, earnings estimate ...

VNDA stock opened at $4.36 on Tuesday. The firm has a market cap of $254.26 million, a price-to-earnings ratio of -13.63 and a beta of 0.72. Vanda Pharmaceuticals Inc. has a 1-year low of $3.85 ...